TriSalus Life Sciences (TLSI) News Today $5.38 +0.04 (+0.65%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cantor Fitzgerald Issues Negative Estimate for TLSI EarningsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for TriSalus Life Sciences in a report released on Monday, May 19th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.90) per sMay 23 at 8:29 AM | marketbeat.comCantor Fitzgerald Has Negative View of TLSI FY2025 EarningsMay 23 at 2:43 AM | americanbankingnews.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22 at 7:53 AM | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $10.93 Average Price Target from AnalystsMay 19, 2025 | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by BrokeragesTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has received a consensus recommendation of "Buy" from the nine research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. ThMay 16, 2025 | marketbeat.comTriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on WednesdayTriSalus Life Sciences (NASDAQ:TLSI) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-21-trisalus-life-sciences-inc-stock/)May 16, 2025 | marketbeat.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comBridgeway Capital Management LLC Purchases 50,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI)Bridgeway Capital Management LLC grew its position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) by 333.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,000 shares of the companyMay 15, 2025 | marketbeat.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Large Decline in Short InterestTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 26,400 shares, a decrease of 78.5% from the March 31st total of 123,000 shares. Based on an average daily volume of 49,800 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.2% of the shares of the stock are sold short.April 29, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of "Buy" by BrokeragesShares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received a consensus rating of "Buy" from the ten research firms that are presently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buyApril 21, 2025 | marketbeat.comTriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on MondayTriSalus Life Sciences (NASDAQ:TLSI) will be releasing earnings before the market opens on Monday, April 7, Financial Modeling Prep reports.March 31, 2025 | marketbeat.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comCanaccord Genuity Group Reiterates Buy Rating for TriSalus Life Sciences (NASDAQ:TLSI)Canaccord Genuity Group reaffirmed a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday.March 29, 2025 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Hits EstimatesTriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) posted its earnings results on Thursday. The company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35).March 28, 2025 | marketbeat.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comTriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Rating of "Buy" from AnalystsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has been given an average rating of "Buy" by the ten analysts that are covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. TMarch 25, 2025 | marketbeat.comTriSalus Life Sciences (TLSI) Projected to Post Earnings on ThursdayTriSalus Life Sciences (NASDAQ:TLSI) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Large Increase in Short InterestTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the target of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 128,000 shares, a growth of 75.3% from the January 31st total of 73,000 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average daily trading volume, of 41,000 shares, the short-interest ratio is currently 3.1 days.March 2, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from AnalystsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has earned a consensus recommendation of "Buy" from the ten brokerages that are covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendaFebruary 28, 2025 | marketbeat.com3 Stocks With Robust Growth Outlooks Insiders Are Buying (TLSI)February 19, 2025 | insidertrades.comTriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Lake Street CapitalLake Street Capital started coverage on shares of TriSalus Life Sciences in a research note on Thursday. They issued a "buy" rating for the company.February 13, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases $33,900.00 in StockFebruary 7, 2025 | insidertrades.comTrisalus Life Sciences CFO buys $33,900 in common stockFebruary 6, 2025 | msn.comJames Emmett Young Purchases 6,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CFO James Emmett Young acquired 6,000 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were bought at an average price of $5.65 per share, with a total value of $33,900.00. Following the transaction, the chief financial officer now owns 30,000 shares in the company, valued at $169,500. This represents a 25.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.February 6, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of "Buy" by AnalystsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has been assigned a consensus rating of "Buy" from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and two have assigned a strong buy recFebruary 3, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Purchases 5,030 SharesFebruary 1, 2025 | insidertrades.comInsider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Buys 5,030 Shares of StockTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary T. Szela acquired 5,030 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was acquired at an average price of $5.03 per share, with a total value of $25,300.90. Following the acquisition, the chief executive officer now owns 439,249 shares in the company, valued at $2,209,422.47. The trade was a 1.16 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.January 31, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Buys 4,826 SharesJanuary 30, 2025 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Acquires $26,156.92 in StockTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary T. Szela purchased 4,826 shares of TriSalus Life Sciences stock in a transaction that occurred on Monday, January 27th. The shares were bought at an average price of $5.42 per share, with a total value of $26,156.92. Following the completion of the transaction, the chief executive officer now owns 429,503 shares of the company's stock, valued at $2,327,906.26. This represents a 1.14 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.January 29, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Purchases $79,650.00 in StockTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) insider Sean Murphy purchased 15,000 shares of the stock in a transaction on Monday, January 27th. The shares were acquired at an average cost of $5.31 per share, for a total transaction of $79,650.00. Following the transaction, the insider now owns 182,732 shares of the company's stock, valued at approximately $970,306.92. The trade was a 8.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.January 29, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young Acquires 24,000 SharesTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CFO James Emmett Young acquired 24,000 shares of TriSalus Life Sciences stock in a transaction dated Monday, January 27th. The shares were purchased at an average price of $5.40 per share, for a total transaction of $129,600.00. Following the completion of the transaction, the chief financial officer now directly owns 24,000 shares in the company, valued at approximately $129,600. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.January 29, 2025 | marketbeat.comTriSalus Life Sciences: Strong Q4 2024 Performance and Promising 2025 Outlook Drive Buy RatingJanuary 25, 2025 | markets.businessinsider.comTriSalus Life Sciences (NASDAQ:TLSI) Earns "Buy" Rating from Roth MkmRoth Mkm restated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday.January 24, 2025 | marketbeat.comTriSalus reports 59% annual revenue growth in 2024January 23, 2025 | msn.comTriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference CallJanuary 23, 2025 | stockhouse.comTriSalus Life Sciences Prelim. Q4 Revenue SurgesJanuary 23, 2025 | markets.businessinsider.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest UpdateTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 83,800 shares, an increase of 45.5% from the December 15th total of 57,600 shares. Currently, 2.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 37,300 shares, the days-to-cover ratio is currently 2.2 days.January 16, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 22.8% in DecemberTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 57,600 shares, a growth of 22.8% from the November 30th total of 46,900 shares. Approximately 1.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 35,900 shares, the days-to-cover ratio is presently 1.6 days.December 29, 2024 | marketbeat.comTriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are CutDecember 24, 2024 | seekingalpha.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Equity Ab Frankenius Acquires 62,972 SharesDecember 20, 2024 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Acquires $249,998.84 in StockTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) major shareholder Equity Ab Frankenius bought 62,972 shares of the company's stock in a transaction on Tuesday, December 17th. The shares were acquired at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the acquisition, the insider now owns 6,230,748 shares in the company, valued at $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.December 19, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Cantor FitzgeraldCantor Fitzgerald started coverage on TriSalus Life Sciences in a research note on Tuesday. They issued an "overweight" rating and a $10.00 price objective on the stock.December 17, 2024 | marketbeat.comNorthland Capmk Has Positive Outlook of TLSI FY2026 EarningsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Investment analysts at Northland Capmk upped their FY2026 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a research note issued on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now forecasts that thNovember 28, 2024 | marketbeat.com Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSI Media Mentions By Week TLSI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TLSI News Sentiment▼-0.210.69▲Average Medical News Sentiment TLSI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TLSI Articles This Week▼111▲TLSI Articles Average Week Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Iradimed News Today Beta Bionics News Today CeriBell News Today Avanos Medical News Today Butterfly Network News Today OrthoPediatrics News Today Bioventus News Today RxSight News Today AxoGen News Today Delcath Systems News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TLSI) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TLSI Stock Free TLSI Stock Alerts